TP53 and cancer: With wild-type p53, the responses of cyclin B1 and phosphorylated cdc2 to NS loss are distinctive between normal and cancer cells, with HCT116 cells showing increases in both phosphorylated cdc2 and cyclin B1 and MEF cells showing no change in phosphorylated cdc2 and a decrease in cyclin B1.